Jaguar Animal Health, Inc. 4
4 · Jaguar Animal Health, Inc. · Filed May 18, 2015
Insider Transaction Report
Form 4
Yang Zhi
Director10% Owner
Transactions
- Conversion
Common Stock
2015-05-18+1,483,326→ 1,522,881 total(indirect: See Footnote) - Conversion
Series A Preferred Stock
2015-05-18−2,224,991→ 0 total(indirect: By Kunlun Pharmaceuticals, Ltd.)→ Common Stock (1,483,326 underlying)
Footnotes (2)
- [F1]These securities automatically converted into Issuer's common stock on a 1.5 for 1 basis immediately prior to the consummation of Issuer's initial public offering ("IPO") and had no expiration date.
- [F2]Represents (i) 39,555 shares held by Sichuan Biopharma ("Sichuan") and (ii) 1,483,326 shares held by Kunlun Pharmaceuticals, Ltd. ("Kunlun"). Sichuan is an investment vehicle of BVCF Management, Ltd. ("BVCF"). Kunlun is directly owned by BVCF III, L.P. and BVCF III-A, L.P. BVCF III, L.P. and BVCF III-A, L.P. are managed by BVCF. The Reporting Person is Chairman, Founder, Managing Partner and sole shareholder of BVCF and may be deemed to have sole voting and dispositive power with respect to the shares held by Sichuan and Kunlun. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.